TY - JOUR T1 - Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin) JF - Journal of Medical Ethics JO - J Med Ethics SP - 187 LP - 189 DO - 10.1136/medethics-2011-100032 VL - 38 IS - 3 AU - Catherine Rhodes AU - John Harris AU - John Sulston AU - Catherine Spanswick Y1 - 2012/03/01 UR - http://jme.bmj.com/content/38/3/187.abstract N2 - There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future. ER -